Metabolomic profiles of current cigarette smokers

Molecular Carcinogenesis

Volumn 56, Issue 2, 2017, Pages 594-606

  Hsu, Ping Ching ^a   Lan, Renny S ^a   Brasky, Theodore M ^a   Marian, Catalin ^a,b   Cheema, Amrita K ^c   Ressom, Habtom W ^c   Loffredo, Christopher A ^c   Pickworth, Wallace B ^d   Shields, Peter G ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c GEORGETOWN UNIVERSITY   (United States)

^d BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

menthol; metabolomics; plasma; smokers; UHPLC QTOF MS

Indexed keywords

BIOLOGICAL MARKER; CYCLIC AMP; GLUCURONIDE; GLUTAMIC ACID; GLYCEROPHOSPHOLIPID; MENTHOL; OLEAMIDE; GLUCURONIC ACID; MENTHOL GLUCURONIDE;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; EXPERIMENTAL DESIGN; FEMALE; HUMAN; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SMOKING; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; METABOLISM; METABOLOME; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; FEMALE; GLUCURONATES; HUMANS; MALE; MENTHOL; METABOLOME; METABOLOMICS; MIDDLE AGED; SMOKING; YOUNG ADULT;

EID: 85007575074     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22519     Document Type: Article

References (49)

1. Berman ML, Connolly G, Cummings KM, et al. Providing a science base for the evaluation of tobacco products. Tobac Regulat Sci 2015; 1:76–93.
2. Patti GJ. Separation strategies for untargeted metabolomics. J Separat Sci 2011; 34:3460–3469.
3. Hsu PC, Zhou B, Zhao Y, et al. Feasibility of identifying the tobacco-related global metabolome in blood by UPLC-QTOF-MS. J Proteome Res 2013; 12:679–691.
4. Mathe EA, Patterson AD, Haznadar M, et al. Non-invasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res 2014.
5. Benowitz NL, Zevin S, Jacob P, 3rd. Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther 1998; 287:958–962.
6. Jacob P, 3rd, Yu L, Duan M, Ramos L, Yturralde O, Benowitz NL. Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: Biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:267–276.
7. Tautenhahn R, Patti GJ, Rinehart D, Siuzdak G. XCMS online: A web-based platform to process untargeted metabolomic data. Anal Chem 2012; 84:5035–5039.
8. Perez-Stable EJ, Benowitz NL, Marin G. Is serum cotinine a better measure of cigarette smoking than self-report? Prev Med 1995; 24:171–179.
9. Gelal A, Jacob P, 3rd, Yu L, Benowitz NL. Disposition kinetics and effects of menthol. Clin Pharmacol Therap 1999; 66:128–135.
10. Hecht SS. Cigarette smoking: Cancer risks, carcinogens, and mechanisms. Langenbecks Arch Surg 2006; 391:603–613.
11. Lawrence D, Cadman B, Hoffman AC. Sensory properties of menthol and smoking topography. Tob Induc Dis 2011; 9:S3.
12. Benowitz NL, Dains KM, Dempsey D, Havel C, Wilson M, Jacob P, 3rd. Urine menthol as a biomarker of mentholated cigarette smoking. Cancer Epidemiol Biomarkers Prev 2010; 19:3013–3019.
13. Goerke J. Pulmonary surfactant: Functions and molecular composition. Biochimica et biophysica acta 1998; 1408:79–89.
14. Canales L, Chen J, Kelty E, et al. Developmental cigarette smoke exposure: Liver proteome profile alterations in low birth weight pups. Toxicology 2012; 300:1–11.
15. Ling YS, Liang HJ, Chung MH, Lin MH, Lin CY. NMR- and MS-based metabolomics: Various organ responses following naphthalene intervention. Mol Biosyst 2014; 10:1918–1931.
16. Munder PG, Modolell M, Andreesen R, Weltzien HU, Westphal O. Lysophosphatidylcholine (lysolecithin) and its synthetic analogues. Immunemodulating and other biologic effects. Springer Sem Immunopathol 1979; 2:187–203.
17. Mehta D. Lysophosphatidylcholine: An enigmatic lysolipid. Am J Physiology Lung Cell Mol Physiol 2005; 289:L174–L175.
18. Ryborg AK, Johansen C, Iversen L, Kragballe K. Lysophosphatidylcholine induces keratinocyte differentiation and upregulation of AP-1- and NF-kappaB DNA-binding activity. Acta dermato-venereologica 2004; 84:433–438.
19. Gillett MP, Besterman EM. Plasma concentrations of lysolecithin and other phospholipids in the healthy population and in men suffering from atherosclerotic diseases. Atherosclerosis 1975; 22:111–124.
20. Aiyar N, Disa J, Ao Z, et al. Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells. Mol Cell Biochem 2007; 295:113–120.
21. Rikitake Y, Kawashima S, Yamashita T, et al. Lysophosphatidylcholine inhibits endothelial cell migration and proliferation via inhibition of the extracellular signal-regulated kinase pathway. Arterioscler Thromb Vasc Biol 2000; 20:1006–1012.
22. Lin P, Welch EJ, Gao XP, Malik AB, Ye RD. Lysophosphatidylcholine modulates neutrophil oxidant production through elevation of cyclic AMP. J Immunol 2005; 174:2981–2989.
23. Ren P, Zhang JG, Xiu L, Yu ZT. Clinical significance of phospholipase A2 group IIA (PLA2G2A) expression in primary resected esophageal squamous cell carcinoma. Eur Rev Med Pharmacol Sci 2013; 17:752–757.
24. Xing XF, Li H, Zhong XY, et al. Phospholipase A2 group IIA expression correlates with prolonged survival in gastric cancer. Histopathology 2011; 59:198–206.
25. Muller DC, Degen C, Scherer G, Jahreis G, Niessner R, Scherer M. Metabolomics using GC-TOF-MS followed by subsequent GC-FID and HILIC-MS/MS analysis revealed significantly altered fatty acid and phospholipid species profiles in plasma of smokers. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 966:117–126.
26. Wang-Sattler R, Yu Y, Mittelstrass K, et al. Metabolic profiling reveals distinct variations linked to nicotine consumption in humans-first results from the KORA study. PloS ONE 2008; 3:e3863.
27. Xu T, Holzapfel C, Dong X, et al. Effects of smoking and smoking cessation on human serum metabolite profile: Results from the KORA cohort study. BMC Med 2013; 11:60.
28. Dong J, Cai X, Zhao L, et al. Lysophosphatidylcholine profiling of plasma: Discrimination of isomers and discovery of lung cancer biomarkers. Metabolomics 2010; 6:478–488.
29. Guo Y, Wang X, Qiu L, et al. Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry. Clinica chimica acta; Int J Clin Chem 2012; 414:135–141.
30. Bisogno T, Katayama K, Melck D, et al. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells-implications for cell proliferation and differentiation. Eur J Biochem/FEBS 1998; 254:634–642.
31. Yang J, Liu B, Wang Q, et al. Connexin 32 and its derived homotypic gap junctional intercellular communication inhibit the migration and invasion of transfected HeLa cells via enhancement of intercellular adhesion. Mol Med Rep 2011; 4:971–979.
32. Brosnan JT. Glutamate, at the interface between amino acid and carbohydrate metabolism. J Nutr 2000; 130:988S–990S.
33. Vulimiri SV, Misra M, Hamm JT, Mitchell M, Berger A. Effects of mainstream cigarette smoke on the global metabolome of human lung epithelial cells. Chem Res Toxicol 2009; 22:492–503.
34. Rahman I, MacNee W. Lung glutathione and oxidative stress: Implications in cigarette smoke-induced airway disease. Am J Physiol 1999; 277:L1067–L1088.
35. Rutten EP, Engelen MP, Wouters EF, Schols AM, Deutz NE. Metabolic effects of glutamine and glutamate ingestion in healthy subjects and in persons with chronic obstructive pulmonary disease. Am J Clin Nutr 2006; 83:115–123.
36. Engelen MP, Schols AM, Does JD, Deutz NE, Wouters EF. Altered glutamate metabolism is associated with reduced muscle glutathione levels in patients with emphysema. Am J Respir Crit Care Med 2000; 161:98–103.
37. Halliwell BB, Poulsen HE. Cigarette smoke and oxidative stress. Germany: Springer; 2007.
38. Mandal A, Mishra S, Mandal P. Sex specific differences in GABA and glutamate levels in response to cigarette smoke. Scientific Rep 2013; 2:1–2.
39. Luksch H, Uckermann O, Stepulak A, et al. Silencing of selected glutamate receptor subunits modulates cancer growth. Anticancer Res 2011; 31:3181–3192.
40. Peters SA, Huxley RR, Woodward M. Do smoking habits differ between women and men in contemporary Western populations? Evidence from half a million people in the UK Biobank study. BMJ Open 2014; 4:e005663.
41. Lee MH, Ahn SV, Hur NW, Choi DP, Kim HC, Suh I. Gender differences in the association between smoking and dyslipidemia: 2005 Korean National Health and Nutrition Examination Survey. Clinica chimica acta; Int J Clin Chem 2011; 412:1600–1605.
42. Yahagi K, Davis HR, Arbustini E, Virmani R. Sex differences in coronary artery disease: Pathological observations. Atherosclerosis 2015; 239:260–267.
43. Munir R, Usman H, Hasnain S, Smans K, Kalbacher H, Zaidi N. Atypical plasma lipid profile in cancer patients: Cause or consequence? Biochimie 2014; 102:9–18.
44. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2011. Bethesda, MD: U. S. National Institutes of Health; 2014.
45. Jagadapillai R, Chen J, Canales L, Birtles T, Pisano MM, Neal RE. Developmental cigarette smoke exposure: Kidney proteome profile alterations in low birth weight pups. Toxicology 2012; 299:80–89.
46. Selige J, Tenor H, Hatzelmann A, Dunkern T. Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition. J Cell Physiol 2010; 223:317–326.
47. Matera MG, Page C, Cazzola M. PDE inhibitors currently in early clinical trials for the treatment of asthma. Exp Opin Invest Drug 2014; 23:1267–1275.
48. Vignola AM. PDE4 inhibitors in COPD—a more selective approach to treatment. Respir Med 2004; 98:495–503.
49. Carrott MJ, Jones DC, Davidson G. Identification and analysis of polymer additives using packed-column supercritical fluid chromatography with APCI mass spectrometric detection. Analyst 1998; 123:1827–1833.